Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revised Japan Prices Include Big Cuts For Gilead HCV Drugs

This article was originally published in PharmAsia News

Executive Summary

With policy surrounding the regular drug price revision in Japan next month finalized and a list of new tariff prices just released, it has become clear that Gilead is facing sizeable reimbursement reductions for its two big-selling hepatitis C drugs in the country.

You may also be interested in...

Industry Fears Realized As Japan Moves To Annual Price Cuts

Against the protests of the innovative pharma industry, Japan is pushing ahead with an overhaul of its drug reimbursement pricing system that will include a shift to annual price revisions.

Japan Slashes Opdivo Price 50% After Prescriptions Surge

Merck’s Keytruda could see its launch price set lower too after Opdivo’s rapidly rising use in lung cancer triggers maximum statutory price cut.

Japan Drug Cost Concerns Rise To The Top

Sharply rising medical spending in Japan, driven in part by expensive new drugs, is now attracting attention at the highest political levels, with a key prime ministerial council set to debate potential cost-cutting measures.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts